Sammenlign metoder
Gjennomgå de valgte metodene side om side; rader som avviker, er uthevet.
| Bayesiansk hierarkisk modell× | Farmakokinetisk kompartmentmodell× | |
|---|---|---|
| Fagfelt≠ | Bayesiansk | Farmakometri |
| Familie≠ | Bayesian methods | Regression model |
| Opprinnelsesår≠ | 2006 | 1982 |
| Opphavsperson≠ | Gelman & Hill (2006); Bayesian multilevel tradition | Gibaldi & Perrier |
| Type≠ | hierarchical probabilistic model | Deterministic ODE-based pharmacokinetic model |
| Opprinnelig kilde≠ | Gelman, A. & Hill, J. (2006). Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge University Press. DOI ↗ | Gibaldi, M., & Perrier, D. (1982). Pharmacokinetics (2nd ed.). Marcel Dekker. ISBN: 978-0-8247-1042-2 |
| Alias≠ | multilevel Bayes, Bayesian multilevel model, Bayesian HLM, partial pooling model | Mammillary Compartment Model, Multi-Compartment PK Model, Compartmental Analysis, Farmakokinetik Kompartman Modeli |
| Relaterte≠ | 4 | 3 |
| Sammendrag≠ | Bayesian hierarchical modelling, popularised by Gelman and Hill (2006), is a Bayesian approach to nested data structures — such as students within schools within districts — that estimates separate parameters at each level while allowing those levels to share statistical strength through a mechanism called partial pooling. Where a classical hierarchical linear model treats group means as fixed unknown quantities, the Bayesian version places hyperprior distributions on those group means so that information flows freely across levels, producing more reliable group-level estimates whenever any individual group has few observations. | The pharmacokinetic compartment model represents the body as one or more hypothetical compartments interconnected by first-order rate processes, describing how a drug is absorbed, distributed, and eliminated over time. Systematized by Gibaldi and Perrier in 1982, these models use ordinary differential equations to characterize plasma concentration-time profiles. They are the cornerstone of drug development, dosage regimen design, and regulatory submission pharmacokinetic analyses. |
| ScholarGateDatasett ↗ |
|
|